| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
| Products Intro: |
Product Name:BavituxiMab
CAS:648904-28-3
Purity:Typically NLT 98%
|
Bavituximab manufacturers
- Bavituximab
-
- $413.00
-
2026-05-21
- CAS:648904-28-3
- Purity: > 95%
- Supply Ability: 10g
|
| | Bavituximab Basic information |
| Product Name: | Bavituximab | | Synonyms: | BAVITUXIMAB;Tarvacin;Research Grade Bavituximab (DGK10101);Anti-PS MAb 3G4;Research Grade Bavituximab;Bavituximab (anti-Phosphatidylserine) | | CAS: | 648904-28-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Bavituximab Structure]() |
| | Bavituximab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Bavituximab Usage And Synthesis |
| Uses | Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1]. | | in vivo | Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo[2].
| Animal Model: | Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors[2] | | Dosage: | 100 μg/mouse (Bavituximab/β2GP1) | | Administration: | Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose) | | Result: | Traced phosphatidylserine exposure in vivo in mice with tumors. |
| | References | [1] Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. DOI:10.1016/j.lungcan.2014.08.010
[2] Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591. DOI:10.1245/s10434-016-5107-5 |
| | Bavituximab Preparation Products And Raw materials |
|